|
|
||||||||
Department of Microbiology and Immunology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202; and Walther Cancer Institute, Indianapolis, IN 46208
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
, and by bacterial components, like LPS that are found in inflamed tissue (2, 3). Activated DCs migrate to T cell areas in lymphoid tissues, transform into mature forms of DCs by up-regulating their T cell costimulatory capacity, and finally acquire high efficiency in presentation of processed pathogen Ags to T cells (4). DCs, depending on their maturation status and the activation signals they receive, modulate T cell differentiation into either Th1 or Th2 cells or into anergic T cells (5, 6, 7). It is unclear whether a subset of DCs exists to induce tolerance. DCs taking up apoptotic cells fail to mature in vivo and induce peripheral tolerance (8). In vitro, immature DCs induce regulatory T cells and T cell anergy, whereas mature DCs induce inflammatory Th1 immune responses (9). Tolerogenic DCs may be explained by absence of maturation stimuli to activate DCs. However, a group of IL-10high-producing DCs, which are located in lymphoid organs in mice and in lung in humans, induced tolerance in vivo (10, 11).
Due to the extremely low frequency of DCs in human peripheral blood, characterization of DC function relies largely on cell culture to obtain sufficient numbers of DCs. In vitro culture of human DCs, from either hemopoietic stem/progenitor cells or monocytes, is dependent on GM-CSF (12, 13, 14). GM-CSF has been ubiquitously included in cultures to generate DCs. GM-CSF expands myeloid DCs in vivo (15). However, GM-CSF null mice and GM-CSF receptor
-chain null mice have normal DC numbers in spleen (16). It appears that GM-CSF is important, but not critical for DC development.
Both GM-CSF and M-CSF are important growth factors for development of monocyte/macrophage lineage (17, 18, 19). GM-CSF and M-CSF induce development of two kinds of macrophages with distinct morphology, phenotype, and function (20). M-CSF-induced macrophages produce a large amount of IL-10, but a minimal level of IL-12 (21). Compared with GM-CSF, M-CSF is constitutively detected in human serum and is greatly elevated in immune suppressive conditions like pregnancy, neonatal cord blood, and tumors (22, 23, 24). Loss of M-CSF induces pregnancy blocking and abortion when M-CSF-deficient mice are mated to nonsyngeneic mice strains (25). Low production of M-CSF during pregnancy is associated with recurrent abortion. This association suggests a possible role for M-CSF in maintaining maternal tolerance toward embryos (26, 27). M-CSF inhibits DC differentiation derived from CD34+ progenitors by down-regulation of CD1a, but up-regulation of CD14 expression (28). There is evidence that M-CSF might be involved in human DC differentiation. M-CSF-deficient mice have >85% reduction of blood monocytes and therefore decreased numbers of monocyte-derived DCs (29). M-CSF, in combination with TGF-
1 can replace GM-CSF to skew human CD34+ progenitor cell differentiation into dendritic Langerhans cells (30). M-CSF is also an essential growth factor for establishing and maintaining a long-term DC line from murine epidermis (31). We have previously shown that monocytes grown in the presence of M-CSF and IL-4 gradually lose markers of the monocyte/macrophage lineage, but gain markers of DCs (32). However, it was not known whether M-CSF could induce monocyte differentiation into DCs with unique functions.
Cord blood has been successfully used as a transplantable source of hemopoietic stem cells with a relatively low incidence of graft-versus-host disease (GVHD) (33, 34, 35, 36, 37, 38, 39, 40). DCs, as the most efficient APCs, have the potential to induce immune activation or tolerance and play a critical role in the pathogenesis of GVHD (1, 41, 42, 43, 44). Monocytes constitute a large pool of DC precursors in cord blood and give rise to DCs under the influence of GM-CSF and IL-4 (45). Cord blood monocyte-derived DCs demonstrate markedly reduced efficiency in secreting IL-12 and inducing Th1 differentiation (46, 47). Study of DCs in cord blood may help to elucidate ways to decrease the incidence of GVHD in cord blood, as well as in bone marrow transplantation. Physiologically, cord blood monocytes might have a greater chance to be exposed to M-CSF and IL-4 because higher serum levels of M-CSF have been detected in cord blood than in adult blood (23, 24) and pregnancy is associated with a skewed Th2 cytokine (IL-4) profile (48). Therefore, we chose to use cord blood to study whether M-CSF, in combination with IL-4 could induce cord blood monocyte differentiation into suppressive DCs. Our results demonstrate that IL-10highIL-12absent accessory cells with DC features (termed M-DCs) are induced from highly purified umbilical cord blood CD14+ monocytes in the presence of M-CSF and IL-4. We have found that both immature and mature M-DCs induce low responsiveness of naive cord blood CD4+ T cells.
| Materials and Methods |
|---|
|
|
|---|
Heparinized umbilical cord blood was collected according to institutional guidelines. PBMC were isolated by density gradient centrifugation on Ficoll Paque Plus (1.077 g/ml; Amersham Pharmacia Biotech). RBC were lysed using Puregene RBC lysis solution (Gentra Systems). Monocytes and CD4+ T cells were purified from PBMC using MACS CD14+ magnetic beads and CD4+ T cell isolation kit (Miltenyi Biotec), respectively. Enriched CD4+ T cells from different cord blood samples were used fresh or were frozen until use. Isolated monocytes and T cells were >98% and >95% pure populations, respectively, as analyzed by flow cytometry.
Cell culture
CD14+ monocytes (5 x 105 cells/ml) were cultured in RPMI 1640 medium (BioWhittaker) supplemented with 10% heat-inactivated FBS (HyClone Laboratories), L-glutamine, HEPES, 50 mM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin for 56 days in the presence of 20 ng/ml recombinant human IL-4 with 400 U/ml recombinant human GM-CSF (Immunex/Amgen) to generate DCs and 100 ng/ml recombinant human M-CSF to generate M-DCs. Culture medium was changed every 3 days unless otherwise indicated. To induce maturation of DCs, 1 µg/ml LPS from Salmonella minnesota (Sigma-Aldrich) or 50 ng/ml TNF-
(Genentech) was added to cultures on day 5 and cells were incubated for an additional 24 h. These are predetermined optimal concentrations of these cytokines. In selected experiments, 1 µg/ml neutralizing polyclonal anti-GM-CSF (R&D Systems) was added each day to the cell cultures. Allogeneic DCs (GM-CSF/IL-4-induced) used in secondary MLR were cultured for up to 3 wk with medium change at 1-wk intervals, and were induced to maturation by addition of LPS the day before cells were used. Harvested cells were counted with trypan blue solution (Sigma-Aldrich) under a hemocytometer.
Assays for cytokine/chemokine production
To detect cytokine secretion, washed cells (2 x 105/ml) were stimulated with LPS (1 µg/ml) in culture medium in 24-well plates for 24 h; supernatants were frozen at 80°C until assayed for cytokines. Cytokine levels in supernatants were measured in duplicate with human IL-10 and human IL-12 (p70) ELISA kits (BD Biosciences). For intracellular analysis of cytokine production, CD4+ T cells (5 x 105/ml), after stimulation with allogeneic DCs as previously described, were activated with 50 ng/ml PMA (Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-Aldrich) in the presence of 10 µg/ml brefeldin A (Sigma-Aldrich) for 56 h. Cells were then fixed, permeabilized (Cytofix/Cytoperm kit; BD Pharmingen), and stained with FITC-labeled IFN-
and PE-labeled anti-IL-4 (BD Biosciences). For intracellular analysis of MIP-1
production, LPS (1 µg/ml; Sigma-Aldrich) was added into day 5 M-DC and DC cultures in the presence of GolgiStop (BD Biosciences) for an additional 16 h. Cells were harvested, fixed, permeabilized before being stained with PE-labeled anti-MIP-1
(BD Biosciences). Samples were then analyzed by flow cytometry (FACSCalibur flow cytometer and CellQuest software; BD Biosciences).
Analysis of DC surface phenotype by flow cytometry
Harvested cells were washed twice with PBS supplemented with 1% BSA. Fc receptors on cells were preblocked with excess human IgG (Sigma-Aldrich) on ice for 15 min. Cells were stained for 30 min at 4°C with the following FITC-conjugated Abs: anti-CD14, anti-CD16, anti-CD40, anti-CD83, anti-CCR5 (BD Pharmingen); anti-HLA-ABC, anti-CD1a (eBioscience); anti-CD80, anti-CD86, anti-CD14, anti-HLA-DR (Caltag Laboratories) and with the following PE-conjugated Abs: anti-CD1a (Caltag Laboratories), anti-B7-H1 (eBioscience), anti-CCR7 and anti-CD83 (BD Pharmingen). Murine IgG1-FITC, IgG1-PE, IgG2a-FITC, and IgG2a-PE from Caltag Laboratories or BD Pharmingen were used as isotype controls. After washing, cells were analyzed by flow cytometry.
FITC-dextran uptake experiments
To measure the endocytic activity of DCs, 5 x 104 DCs were incubated with 0.1 mg/ml FITC-dextran (Sigma-Aldrich) in 100 µl of culture medium at 37°C and 0°C (as a control) for 1 h. Cells were then washed with ice-cold PBS supplemented with 1% BSA four times before analysis by flow cytometry.
Expansion of CFSE-labeled CD4+ T cells
CD4+ T cells were suspended in PBS at 5 x 107/ml. A final concentration of 20 µM CFSE (Molecular Probes) was added to the cell suspension and incubated for 5 min at room temperature. Cells were washed three times in RPMI 1640 with 5% FBS. CFSE-labeled CD4+ T cells (5 x 105/ml) were cocultured with mature DCs or M-DCs (5 x 104/ml) in X VIVO-20 serum-free medium in flat-bottom plates. T cells were harvested on day 6 and analyzed by flow cytometry.
Primary and secondary MLR
Primary and secondary MLRs were done in either RPMI 1640 culture medium with 10% FBS or X VIVO-20 serum-free medium (Invitrogen Life Technologies). Primary MLR was established in 96-well U-bottom cell culture plates (Costar) with 1 x 105 responding cord blood CD4+ T cells per well and allogeneic stimulators at E:T target cell ratios ranging from 1:10 to 1:2500 in triplicate. Cells were pulsed with [methyl-3H]thymidine (1 µCi/well; Amersham Pharmacia Biotech) for 16 h before the end of the culture on day 6 and harvested onto glass fiber filter. Incorporated thymidine was measured using a scintillation counter (Microbeta; Wallac).
For secondary MLR, 4 x 106 naive CD4+ T cells were first stimulated with 4 x 105 allogeneic stimulators in six-well plates for 6 days. Cells were then collected, washed, and rested for 48 h in cultured medium supplemented with 2 U/ml human IL-2 (eBioscience). Subsequently, viable T cells (5 x 104/well) were restimulated with 5 x 103 DCs generated from the same donor as used for the first culture in the presence or absence of 50 U/ml IL-2 in U-bottom 96-well plates. T cell proliferation was measured on day 3 or day 5 after a 16-h pulse with [methyl-3H]thymidine (1 µCi/well) before the end of culture.
Alternatively, 4 x 106 naive CD4+ T cells (donor A) were cultured with 4 x 105 allogeneic M-DCs or DCs (donor B) in six-well plates for 7 days. T cells were harvested and enumerated by trypan blue exclusion. Harvested T cells (2.5 x 104/well from donor A) were restimulated with GM-CSF/IL-4-induced mature DCs (donor B) at an E:T ratio of 1:5. T cell proliferation was measured by pulsing cells with [methyl-3H]thymidine (1 µCi/well) for 16 h before the end of culture on day 6. In another experiment, harvested T cells (2.5 x 104/well from donor A) were added into an independently set-up MLR containing naive CD4+ T cells (5 x 104/well; donor A) and GM-CSF/IL-4-induced mature DCs (5 x 103/well; donor B) to examine whether harvested T cells could suppress the independently set-up MLR. T cell proliferation was measured by pulsing cells with [methyl-3H]thymidine (1 µCi/well) for 16 h before the end of culture on day 6.
Statistical analysis
The two-tailed paired Students t test was used to determined statistical significance unless otherwise indicated. Values of p < 0.05 were considered significant.
| Results |
|---|
|
|
|---|
M-CSF and GM-CSF induce monocyte differentiation into macrophages with distinct phenotype and functions (20). IL-4 inhibits macrophage development and, when used in combination with GM-CSF, reprograms monocyte differentiation into DCs instead of macrophages (49, 50). We examined cord blood monocyte differentiation induced by M-CSF/IL-4 in comparison with GM-CSF/IL-4. Cord blood CD14+ monocytes (>98% purity) were cultured with M-CSF alone, or with M-CSF or GM-CSF in the presence of IL-4 for 5 days. In the presence of M-CSF alone, monocytes became strongly adherent and elongated with spindle-like morphology, a typical macrophage morphology as previously reported (Fig. 1, upper left panel) (51). M-CSF-induced macrophages expressed the monocyte/macrophage markers CD14 and CD64 and a low level of HLA-DR (Fig. 2). When cultured with GM-CSF and IL-4 (Fig. 1, middle left panel), monocytes gave rise to typical DCs. Compared with GM-CSF/IL-4-induced DCs, monocytes cultured with M-CSF and IL-4 floated less and had dendrites or protruding projections (Fig. 1, lower left panel) and no osteoclast-like cells were generated in 1 wk of cell culture as assessed by Giemsa staining (data not shown). As assessed by phenotype, increasing doses of IL-4 skewed monocyte differentiation into a novel type of CD14CD64HLA-DRhigh cells instead of CD14+CD64+HLA-DRlow macrophages (Fig. 2). Upon LPS stimulation, cells grown with M-CSF/IL-4 responded to LPS in a way quite different from DCs grown with GM-CSF/IL-4; they tended to form large aggregates surrounded by single cells displaying very long dendrites or spindle-like protrusions (Fig. 1, lower right panel), a morphology similar to LPS-activated M-CSF-induced macrophages (Fig. 1, upper right panel). In contrast, such long dendrites were absent in LPS-stimulated DCs, and LPS-activated DCs formed relatively small aggregates (Fig. 1, middle right panel), as previously reported (50). Monocytes cultured with M-CSF/IL-4 were CD1a (Fig. 3A). Upon activation with LPS or TNF-
, they significantly up-regulated surface expression of CD83, a human DC marker, at a slightly lower or similar level as DCs induced by GM-CSF/IL-4 (Fig. 3B). For simplicity, we termed monocytes driven by M-CSF/IL-4 as M-DCs, in contrast to DCs induced by GM-CSF/IL-4. M-DCs, regardless of their maturation state, expressed the functional molecules CD86, B7-1H, HLA-DR, HLA-ABC, and CD40, as did DCs with only quantitative differences. Before maturation, M-DC had a higher surface expression of HLA-DR, HLA-ABC, and CD86 than DCs. After LPS stimulation, DCs significantly up-regulated expression of HLA-DR and CD86 to a level similar to that of LPS-stimulated M-DCs (Fig. 3, A and B). In addition, M-DCs expressed lower amounts of CD40 and B7-H1 on their surface than DCs regardless of their maturation states (Fig. 3, A and B). Generation of M-DCs appeared to be independent of GM-CSF. Daily addition of neutralizing anti-GM-CSF (1 µg/ml) to DC cultures completely blocked CD1a up-regulation induced by GM-CSF (data not shown). However, anti-GM-CSF failed to block generation of M-DCs as analyzed by morphology and surface staining (data not shown).
|
|
|
as well as a significantly reduced level of CCR5 on DCs (Fig. 3B), possibly due to the internalization of the CCR5 by the produced MIP-1
. In comparison with DCs, M-DCs expressed a minimal level of CCR5 and a detectable level of CXCR4 before and after maturation (Fig. 3, A and B). M-DCs also produced a large amount of MIP-1
upon LPS stimulation (Fig. 3B). As M-DCs and DCs had different expression of CD1a, we investigated whether M-CSF competed with GM-CSF in generation of M-DCs. GM-CSF (40 U/ml) increased the percentage of CD1a+ cells in M-DC cultures; this effect peaked at 200 U/ml GM-CSF (Fig. 4A). However, if GM-CSF was added into day 4 M-DC cultures, GM-CSF failed to induce the appearance of CD1a+ DCs (Fig. 4B). Therefore, it appears that GM-CSF competes with M-CSF in generation of CD1a+ DCs before the M-DC differentiation program initiates.
|
|
M-CSF-induced macrophages are known to produce increased levels of IL-10, but to turn off IL-12 production compared with GM-CSF/IL-4-induced DCs (21). We compared the cytokine secretion profile of M-DCs with DCs. We found that LPS-induced M-DCs produced much higher levels (up to 26-fold) of the anti-inflammatory cytokine IL-10 than DCs (Fig. 6). M-DCs produced nondetectable IL-12 upon LPS stimulation (detection limit, 4 pg/ml). There was great variability of IL-12 production among individual cord blood samples. In three cord blood samples we tested, we detected 385, 73, and 7.2 pg/ml IL-12p70 in LPS-activated DCs. However, M-DCs produced a lower level of IL-12p70 than DCs (Fig. 6). Therefore, with IL-4 included in the culture, M-DCs still produced high amounts of IL-10, but no IL-12 production, a pattern similar to M-CSF-induced macrophages (21).
|
A key feature of mature DCs is their high capacity for priming T cells. Therefore, we further compared alloreactivity of LPS-matured M-DCs with DCs. In an allogeneic MLR, mature M-DCs induced significantly less proliferation of allogeneic naive CD4+ T cells than mature DCs (Fig. 7A).
|
Mature M-DCs induce less Th1 differentiation than mature DCs
IL-10 production by DCs has been reported to be involved in the induction of Th2 differentiation. We compared the two types of mature DCs in driving T cell differentiation by analyzing intracellular levels of IFN-
, IL-4, and IL-10 in T cells. We failed to detect significant amounts of IL-4 and IL-10 (<5%; data not shown) by T cells primed with both types of DCs (Fig. 8) by intracellular staining. IFN-
production with regard to the percentage of IFN-
-producing T cells and its amount of median fluorescence intensity (MFI) secreted by T cells were consistently lower for mature M-DCs than for mature DCs regardless of the presence or absence of IL-12 (p < 0.05) (Fig. 8). For both types of DCs, IL-12 did not increase the percentage of IFN-
-producing T cells, but dramatically enhanced the MFI of cells in the right (R) quadrant in Fig. 8A. These results suggest that mature M-DCs induce less Th1 differentiation than mature DCs. IL-12 increased the amount of IFN-
production per cell, but failed to enhance the percentage of IFN-
-producing T cells. Therefore, IL-12 could not fully compensate for the differences in IFN-
production observed between mature M-DCs and mature DCs.
|
As M-DCs were IL-10highIL-12absent cells and failed to induce T cells to produce significant amounts of Th2 cytokine IL-4, we evaluated the tolerogenic potential of M-DCs. For this purpose, we analyzed CD4+ T cells stimulated with M-DCs for their capacity to respond to secondary stimulation by alloantigen in comparison with DCs. Naive CD4+ T cells, after being stimulated by M-DCs or DCs in primary MLC, were harvested, rested for 2 days, and then restimulated by allogeneic DCs generated from the same donor as that used in the primary MLC. Both M-DCs and DCs before their maturation induced hyporesponsiveness of T cells in secondary MLR in comparison with mature DCs on day 3 and day 5 (Fig. 9A). We further examined whether mature M-DCs could induce hyporesponsiveness of CD4+ T cells. Secondary MLRs were done in both serum-free and serum-containing medium. We found that mature M-DCs induced significantly lower proliferation of T cells in secondary MLR than mature DCs (Fig. 9B). This effect varied among individuals and secondary MLR of T cells primed with mature M-DCs during primary MLR decreased 30, 62, and 68% (for serum-containing medium) and 20, 42, and 63% (for serum-free X VIVO-20 medium) compared with those preprimed with mature DCs. Interestingly, we found in some cord blood samples, even mature DCs poorly induced optimal T cell proliferation in secondary MLR, and IL-2 addition dramatically enhanced the rate of T cell proliferation (Fig. 9B; lower panel). This might be due to special characteristics of cord blood DCs, such as their defect in IL-12 production (46). This low responsiveness of T cells primed by M-DCs could not be blocked by neutralizing anti-IL-10 Abs and was not alloantigen-specific as T cells primed with mature M-DCs in primary MLC also responded less efficiently to allogeneic DCs generated from a third-party donor (data not shown).
|
Because repetitive stimulation of naive CD4+ T cells with immature monocyte-derived DCs induce tolerance and regulatory T cells (9), we examined whether immature DC (M-DC and DC) generated in our hands could induce regulatory T cells. For this purpose, naive CD4+ T cells were cultured with immature M-DC and DC for 7 days, respectively. For simplicity, we termed T cells at the end of culture as T1 (cultured with immature M-DC) and T2 (cultured with immature DC). As shown in Fig. 10, T1 and T2 were added into an independently set-up MLR consisting of naive CD4+ T cells and GM-CSF/IL-4-induced DC to examine whether T1 and T2 could suppress MLR. At a T1 or T2 to naive T cell ratio of 1:2, T1 and T2 efficiently switched off MLR of naive T cells by 87% (Fig. 10), 75%, and 85% (data not shown) for T1 and by 75% (Fig. 10), 85%, and 83% (data not shown) for T2. These results demonstrate that single time stimulation of naive CD4+ T cells with both types of immature DCs derived from cord blood induced the appearance of regulatory T cells.
|
We investigated whether mature M-DC could induce regulatory T cells. Therefore, naive CD4+ T cells were cultured for 7 days with mature M-DC and mature DC, respectively. T cells harvested at the end of culture were called T3 (cultured with mature M-DC) and T4 (cultured with mature DC), respectively, for simplicity. First, T3 and T4 were restimulated with GM-CSF/IL-4-induced DC in a 2°MLR to confirm the results observed in Fig. 9B that T3 could induce hyporesponsiveness in T cells in 2°MLR. Next, T3 and T4 were then added into an independently set-up MLR containing naive CD4+ T cells and GM-CSF/IL-4-induced DCs to assay whether T3 could suppress MLR. Results from four donors revealed individual variation. Half of the donor-derived mature M-DCs induced regulatory T cells (Fig. 11, left), whereas the other half of the mature M-DCs induced T cell anergy, but no regulatory T cells (Fig. 11, right). As shown in Fig. 11, T3 after priming with mature M-DC does not respond well to restimulation by GM-CSF/IL-4-induced DC in 2°MLR (Fig. 11, top). Furthermore, T3 efficiently suppressed the independently set-up MLR by 70% (Fig. 11, left) and 74% (data not shown), demonstrating that T3 contains regulatory T cells for the two donors. For the other two donors, as shown in Fig. 11, T3 after priming with mature M-DC did not respond well to restimulation by GM-CSF/IL-4-induced DC in 2°MLR (top). However, T3 only suppressed the independently set-up MLR by 13.4% (Fig. 11, right part) and 7.4% (data not shown), and T3 and naive T cells proliferated at the same level as naive T cells alone (Fig. 11, bottom right), demonstrating that T3 only induced hyporesponsiveness, but not regulatory T cells. In contrast, T4 prestimulated with mature DC proliferated well in 2°MLR and failed to become hyporesponsive T cells.
|
| Discussion |
|---|
|
|
|---|
M-CSF-induced macrophages produced increased levels of IL-10, but no IL-12 (21). As IL-4 is required for differentiation into M-DCs, we compared production of IL-10 and IL-12 between M-DCs and DCs. In contract to DCs, M-DCs produce high IL-10, but no IL-12, a pattern similar to previously reported M-CSF-induced macrophages. Therefore, IL-4 does not neutralize production of IL-10 and IL-12 by M-CSF-induced macrophages. This finding is in contrast with GM-CSF-induced macrophages producing minimal or no IL-12, although GM-CSF/IL-4-induced DCs produce high levels of IL-12 (21).
The M-DC phenotypes were reproducible in adult monocytes cultured with M-CSF and IL-4 with regard to the expression of CD83, CD40, CD80, CD86, and HLA-DR, CD14, CD64 (data not shown). Consistent with our previous report (32) and described in this study (our unpublished observations) on adult blood monocytes, cord blood M-DCs before their maturation did not show obvious deficiencies in induction of MLR and in driving Th1 differentiation in comparison with cord blood DCs (data not shown). Stimulating once with both types of cord blood-derived DCs (M-DC and DC) potently induced the appearance of regulatory T cells (Fig. 10). However, after receiving maturation signals, M-DCs act as anti-inflammatory accessory cells and induce hyporesponsiveness in T cells in contrast to mature DCs. These features of M-DCs might make them a more effective and safer candidate for the purpose of induction of tolerance. Although immature DCs cultured with GM-CSF and IL-4 induce anergy (9), the tolerogenic ability of immature DCs may not be applicable for induction of tolerance in vivo because immature DCs could receive maturation signals in vivo and transform into mature DCs, therefore inducing immune reactions instead of tolerance. M-DCs produce large amounts of IL-10 upon activation signals. Furthermore, their mature form induces hypo- or low responsiveness in T cells and would be less likely than those of GM-CSF-derived DCs to induce inflammatory T cell responses. By producing IL-10 and inhibiting efficient T cell responses to foreign Ag, M-CSF-induced DCs might provide an immune environment favorable for blocking the host immune responses to foreign Ags. These features of M-DCs make them a possible candidate for the purpose of induction of tolerance for the treatment of transplantation rejection. Our study also supports the hypothesis that there is a subset of high IL-10-producing DCs that could induce tolerance regardless of their maturation state, and M-CSF might be an important cytokine for the development of such types of DCs.
IL-10 is a multifunctional cytokine acting on many hemopoietic cell types. The primary function of IL-10 appears to be inhibition of inflammatory immune responses. IL-10 treatment of DCs induces a state of anergy in alloantigen or peptide Ag-activated T cells (62). IL-10-producing DCs have been identified in Peyers patches and liver in mice; this population of DCs is associated with development of either T cell anergy or Th2 responses (63, 64). In vitro CD34+ stem/progenitor cell-derived DCs fail to produce IL-10, and CD14+ monocyte-derived DCs only produce low levels of IL-10 (65, 66). M-DCs produce large amounts of IL-10; this population of accessory cells could be a novel type of DCs similar to the in vivo-identified IL-10-producing DCs capable of induction of T cell anergy in vivo (10, 11).
M-CSF-induced monocyte-to-DC differentiation appears to be GM-CSF-independent. In contrast to GM-CSF, M-CSF is constitutively detected in serum of healthy donors and its level is greatly elevated in serum, most tissues and especially in the uterus (1000-fold increase) during pregnancy (22, 23). Furthermore, higher serum levels of M-CSF are detected in neonatal cord blood than in adult blood (23, 24). Pregnancy correlates with skewed Th2-type cells and suppressive immune responses that favor the development of maternal T cell tolerance (48). The unique characteristics of the cord blood immune system also leads to a relatively low incidence of GVHD when cord blood is used in transplantation (40). High M-CSF levels detected in pregnancy and in cord blood might induce the appearance of more M-DCs with tolerogenic potential as described in our study, thus suppressing immune reactions during pregnancy and the neonatal period. We hypothesized that because cord blood monocytes have been pre-exposed to a rich cytokine environment (M-CSFhigh and IL-4) during pregnancy and might have been preprogrammed to differentiate along the M-DC pathway before being cultured in vitro with GM-CSF and IL-4 to generate DCs, this might lead to defects in IL-12 production and induction of Th1 differentiation by cord blood-derived DCs in comparison with adult blood monocyte-derived DCs.
M-CSF released by renal cell carcinoma cell lines inhibits differentiation of CD34+ progenitors into DCs. The combination of M-CSF and IL-6 also inhibits DC differentiation. Interestingly, IL-4 reverses the inhibitory effect of M-CSF on the phenotypic and functional differentiation of CD34+ progenitors into DCs (28, 67). Our results suggest an alternative mechanism of M-CSF in DC differentiation. Instead of blocking DC differentiation, M-CSF, in combination with IL-4, might induce generation of suppressive DCs, resulting in nonresponsiveness of the immune system to tumors.
DC function is intimately linked to their capacity to migrate (52). Due to the rarity of human DCs in vivo, most studies took advantage of in vitro GM-CSF-generated DCs to characterize DC migration properties (55). Consistent with previous reports on adult monocyte-derived DCs, immature DCs expressed CCR5, low amounts of CXCR4, but no CCR6 (55, 68). Maturation induced the up-regulation of CXCR4 and the production of CCR5 ligand, MIP-1
and rapidly down-modulated expression of CCR5 (68), possibly due to internalization of CCR5. In contrast to regular DCs, M-DCs expressed a minimal level of CCR5 regardless of maturation state. Immature M-DCs expressed a decreased level of CCR5 in comparison with DCs. Therefore, due to the DC heterogeneity, M-DCs might locate distinctly from DCs and function to suppress efficient immune reactions. These locations might include tumor stroma, placenta, bone marrow, etc. in which M-CSF is constitutively produced (22, 23, 24, 28, 69). It is noted that both M-DC and DC, after LPS-induced maturation, failed to express CCR6 and CCR7 (n = 3, data not shown), chemokine involved in homing of DCs in lymphoid organs (52, 53, 54, 55). Whether this is a special feature, an intrinsic homing defect of cord blood DCs, or a mechanism of nonefficient immune responses in cord blood are not yet known.
Using cord blood monocytes, cells minimally or not exposed to pathogens, tumors, and the aging process, we have noted a novel pathway of monocyte differentiation and have identified and characterized a special type of IL-10high-producing anti-inflammatory accessory cells with DC features. As mentioned, adult blood monocytes can be induced with M-CSF and IL-4 into phenotypic M-DCs. It remains to be determined whether adult blood monocytes have a similar capability for differentiation into functional M-DCs. This finding may be of relevance to DC-based therapeutic applications in cord blood, as well as adult bone marrow transplantation and autoimmune diseases.
| Disclosures |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
1 This work was supported in part by U.S. Public Health Service Grants R01 DK53674, R01 HL67384, and R01 HL56416 from the National Institutes of Health (to H.E.B.) and by Indiana University School of Medicine Aging Fellowship (to G.L.). ![]()
2 Address correspondence and reprint requests to Dr. Hal E. Broxmeyer, Walther Oncology Center, R2-302, Indiana University School of Medicine, 950 West Walnut Street, Indianapolis, IN 46202-5181. E-mail address: hbroxmey{at}iupui.edu ![]()
3 Abbreviations used in this paper: DC, dendritic cell; M-DC, IL-10highIL-12absent accessory cells with a DC phenotype; MFI, median fluorescence intensity; GVHD, graft-versus-host disease. ![]()
Received for publication July 27, 2004. Accepted for publication February 3, 2005.
| References |
|---|
|
|
|---|
. J. Exp. Med. 179:1109.
cooperate in the generation of dendritic Langerhans cells. Nature 360:258.[Medline]
. J. Exp. Med. 182:1111.
1 induces the differentiation of CD34+ hematopoietic progenitor cells into Langerhans cells under serum-free conditions without granulocyte-macrophage colony-stimulating factor. J. Invest. Dermatol. 120:256.[Medline]
. J. Hematother. Stem Cell Res. 9:453.[Medline]
on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell. Immunol. 129:351.[Medline]
and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors. J. Leukocyte Biol. 66:781.[Abstract]
This article has been cited by other articles:
![]() |
A. Puig-Kroger, E. Sierra-Filardi, A. Dominguez-Soto, R. Samaniego, M. T. Corcuera, F. Gomez-Aguado, M. Ratnam, P. Sanchez-Mateos, and A. L. Corbi Folate Receptor {beta} Is Expressed by Tumor-Associated Macrophages and Constitutes a Marker for M2 Anti-inflammatory/Regulatory Macrophages Cancer Res., December 15, 2009; 69(24): 9395 - 9403. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ghafoori, T. Yoshimura, B. Turpie, and S. Masli Increased I{kappa}B{alpha} expression is essential for the tolerogenic property of TGF-{beta}-exposed APCs FASEB J, July 1, 2009; 23(7): 2226 - 2234. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Xia, Z. Guo, X. Xu, H. Yi, Q. Wang, and X. Cao Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance Blood, October 15, 2008; 112(8): 3175 - 3185. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. S. Lee, Y. M. Wang, Y. P. Wang, D. Zheng, T. Polhill, Q. Cao, H. Wu, I. E. Alexander, S. I. Alexander, and D. C. H. Harris Regulatory immune cells in kidney disease Am J Physiol Renal Physiol, August 1, 2008; 295(2): F335 - F342. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Lo, P. Gorak-Stolinska, V. Bachy, M. A. Ibrahim, D. M. Kemeny, and J. Maher Modulation of dendritic cell differentiation by colony-stimulating factor-1: role of phosphatidylinositol 3'-kinase and delayed caspase activation J. Leukoc. Biol., December 1, 2007; 82(6): 1446 - 1454. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Kim and H. E. Broxmeyer Myeloid Derived Dendritic Cells Inhibit CD8+ T Cell Responses by Down-Modulating NKG2D and 4 1BB Expression. Blood (ASH Annual Meeting Abstracts), November 16, 2007; 110(11): 315 - 315. [Abstract] |
||||
![]() |
D. M. Bodine Dendritic cells reach out in different directions Blood, October 15, 2007; 110(8): 2783 - 2783. [Full Text] [PDF] |
||||
![]() |
G. Li, S. Abediankenari, Y.-J. Kim, T. B. Campbell, S. Ito, B. Graham-Evans, S. Cooper, and H. E. Broxmeyer TGF-{beta} combined with M-CSF and IL-4 induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-induced ex vivo expansion of myeloid progenitors Blood, October 15, 2007; 110(8): 2872 - 2879. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Zhang, S. Basu, F. Wu, C. G. Begley, C. J. M. Saris, A. R. Dunn, A. W. Burgess, and F. Walker Macrophage-colony stimulating factor is required for the production of neutrophil-promoting activity by mouse embryo fibroblasts deficient in G-CSF and GM-CSF J. Leukoc. Biol., October 1, 2007; 82(4): 915 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Kwan, C. Boix, N. Gougelet, W. H. Fridman, and C. G. F. Mueller LPS induces rapid IL-10 release by M-CSF-conditioned tolerogenic dendritic cell precursors J. Leukoc. Biol., July 1, 2007; 82(1): 133 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Matthews, U. F. Power, and D. J. Reen Neonatal human autologous dendritic cells pulsed with recombinant protein antigen prime the generation of non-polarized CD4 T-cell effectors Int. Immunol., June 1, 2007; 19(6): 703 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li, S. Basu, M.-K. Han, Y.-J. Kim, and H. E. Broxmeyer Influence of ERK activation on decreased chemotaxis of mature human cord blood monocyte-derived dendritic cells to CCL19 and CXCL12 Blood, April 15, 2007; 109(8): 3173 - 3176. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sanarico, A. Ciaramella, A. Sacchi, D. Bernasconi, P. Bossu, F. Mariani, V. Colizzi, and S. Vendetti Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response J. Leukoc. Biol., September 1, 2006; 80(3): 555 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rutella, S. Danese, and G. Leone Tolerogenic dendritic cells: cytokine modulation comes of age Blood, September 1, 2006; 108(5): 1435 - 1440. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Van Ginderachter, S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer Blood, July 15, 2006; 108(2): 525 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. W. Verreck, T. de Boer, D. M. L. Langenberg, L. van der Zanden, and T. H. M. Ottenhoff Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-{gamma}- and CD40L-mediated costimulation J. Leukoc. Biol., February 1, 2006; 79(2): 285 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Bonfield, C. M. Swaisgood, B. P. Barna, C. F. Farver, M. S. Kavuru, and M. J. Thomassen Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor J. Leukoc. Biol., January 1, 2006; 79(1): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jozefowski, M. Arredouani, T. Sulahian, and L. Kobzik Disparate Regulation and Function of the Class A Scavenger Receptors SR-AI/II and MARCO J. Immunol., December 15, 2005; 175(12): 8032 - 8041. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |